Alison L. Hannah

7.3k total citations · 1 hit paper
122 papers, 4.9k citations indexed

About

Alison L. Hannah is a scholar working on Oncology, Molecular Biology and Hematology. According to data from OpenAlex, Alison L. Hannah has authored 122 papers receiving a total of 4.9k indexed citations (citations by other indexed papers that have themselves been cited), including 67 papers in Oncology, 61 papers in Molecular Biology and 33 papers in Hematology. Recurrent topics in Alison L. Hannah's work include Cancer Treatment and Pharmacology (35 papers), Multiple Myeloma Research and Treatments (21 papers) and Cancer therapeutics and mechanisms (17 papers). Alison L. Hannah is often cited by papers focused on Cancer Treatment and Pharmacology (35 papers), Multiple Myeloma Research and Treatments (21 papers) and Cancer therapeutics and mechanisms (17 papers). Alison L. Hannah collaborates with scholars based in United States, United Kingdom and Spain. Alison L. Hannah's co-authors include Hope S. Rugo, Sara A. Hurvitz, Johannes Ettl, Lida A. Mina, Louis Fehrenbacher, Alison Stopeck, W. Eiermann, Rinat Yerushalmi, Henri Roché and Anthony Gonçalvès and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Alison L. Hannah

117 papers receiving 4.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation

2018 1.4k citations Jennifer K. Litton, Hope S. Rugo et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Alison L. Hannah United States	31	2.5k	2.5k	1.2k	766	763	122	4.9k
Lia Gore United States	43	2.6k 1.0×	2.6k 1.0×	821 0.7×	1.1k 1.4×	632 0.8×	202	6.1k
James A. Zwiebel United States	44	2.5k 1.0×	4.7k 1.9×	741 0.6×	801 1.0×	933 1.2×	140	7.3k
Charles Lu United States	24	1.7k 0.7×	3.6k 1.5×	890 0.7×	985 1.3×	2.1k 2.8×	49	6.3k
Naoko Takebe United States	38	3.2k 1.3×	4.3k 1.7×	925 0.8×	421 0.5×	1.5k 2.0×	181	7.4k
Anne W. Hamburger United States	29	2.2k 0.9×	2.7k 1.1×	555 0.5×	577 0.8×	764 1.0×	110	4.9k
Tajhal Dayaram United States	19	2.3k 0.9×	2.9k 1.1×	2.4k 2.0×	1.1k 1.4×	1.1k 1.5×	26	5.6k
Pier Francesco Ferrucci Italy	37	3.7k 1.5×	2.9k 1.2×	857 0.7×	1.2k 1.6×	409 0.5×	141	6.2k
Stefano Indraccolo Italy	47	2.5k 1.0×	3.5k 1.4×	828 0.7×	367 0.5×	2.2k 2.9×	209	7.0k
Raoul Tibes United States	34	1.5k 0.6×	3.6k 1.5×	418 0.4×	1.4k 1.9×	576 0.8×	144	5.3k
Kathryn Packman United States	28	2.2k 0.9×	2.6k 1.0×	481 0.4×	302 0.4×	484 0.6×	65	3.9k

Countries citing papers authored by Alison L. Hannah

Since Specialization

Citations

This map shows the geographic impact of Alison L. Hannah's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alison L. Hannah with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alison L. Hannah more than expected).

Fields of papers citing papers by Alison L. Hannah

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alison L. Hannah. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alison L. Hannah. The network helps show where Alison L. Hannah may publish in the future.

Co-authorship network of co-authors of Alison L. Hannah

This figure shows the co-authorship network connecting the top 25 collaborators of Alison L. Hannah. A scholar is included among the top collaborators of Alison L. Hannah based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alison L. Hannah. Alison L. Hannah is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Johnson, Melissa L., Anthony B. El-Khoueiry, Navid Hafez, et al.. (2021). Phase I, First-in-Human Study of the Probody Therapeutic CX-2029 in Adults with Advanced Solid Tumor Malignancies. Clinical Cancer Research. 27(16). 4521–4530. 45 indexed citations

Tannir, Nizar M., Neeraj Agarwal, Sumanta K. Pal, et al.. (2020). PIVOT-09: A phase III randomized open-label study of bempegaldesleukin (NKTR-214) plus nivolumab versus sunitinib or cabozantinib (investigator's choice) in patients with previously untreated advanced renal cell carcinoma (RCC).. Journal of Clinical Oncology. 38(6_suppl). TPS763–TPS763. 16 indexed citations

Turner, Nicholas C., Melinda L. Telli, Hope S. Rugo, et al.. (2018). A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline BRCA1/2 Mutations (ABRAZO). Clinical Cancer Research. 25(9). 2717–2724. 88 indexed citations

Rugo, Hope S., Javier Cortés, Ahmad Awada, et al.. (2018). Change in Topoisomerase 1–Positive Circulating Tumor Cells Affects Overall Survival in Patients with Advanced Breast Cancer after Treatment with Etirinotecan Pegol. Clinical Cancer Research. 24(14). 3348–3357. 17 indexed citations

Litton, Jennifer K., Hope S. Rugo, Johannes Ettl, et al.. (2018). Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. New England Journal of Medicine. 379(8). 753–763. 1401 indexed citations breakdown →

Cortés, Javier, Hope S. Rugo, Ahmad Awada, et al.. (2017). Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial. Breast Cancer Research and Treatment. 165(2). 329–341. 36 indexed citations

Kristeleit, Rebecca, T.R. Jeffry Evans, Alvaro Ingles Garces, et al.. (2017). Phase 1/2a trial of daily oral BAL101553, a novel tumor checkpoint controller (TCC), in advanced solid tumors.. Journal of Clinical Oncology. 35(15_suppl). 2532–2532. 1 indexed citations

Kernan, Nancy A., Paul G. Richardson, Angela R. Smith, et al.. (2015). Defibrotide for the Treatment of Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome with/without Multi-Organ Dysfunction Following Chemotherapy: Results from an Ongoing Expanded Access Program. Blood. 126(23). 3121–3121. 1 indexed citations

Jhaveri, Komal, Kathy D. Miller, Lee S. Rosen, et al.. (2012). A Phase I Dose-Escalation Trial of Trastuzumab and Alvespimycin Hydrochloride (KOS-1022; 17 DMAG) in the Treatment of Advanced Solid Tumors. Clinical Cancer Research. 18(18). 5090–5098. 49 indexed citations

10.

Modi, Shanu, Alison Stopeck, Hannah Linden, et al.. (2011). HSP90 Inhibition Is Effective in Breast Cancer: A Phase II Trial of Tanespimycin (17-AAG) Plus Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer Progressing on Trastuzumab. Clinical Cancer Research. 17(15). 5132–5139. 328 indexed citations

11.

Lam, Elaine T., Sanjay Goel, Larry J. Schaaf, et al.. (2011). Phase I dose escalation study of KOS-1584, a novel epothilone, in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 69(2). 523–531. 15 indexed citations

12.

Papadopoulos, Kyriakos P., David S. Siegel, Seema Singhal, et al.. (2010). Phase 1b Evaluation of the Safety and Efficacy of a 30-Minute IV Infusion of Carfilzomib In Patients with Relapsed and/or Refractory Multiple Myeloma. Blood. 116(21). 3024–3024. 5 indexed citations

13.

Richardson, Paul G., Marcie Tomblyn, Nancy A. Kernan, et al.. (2009). Defibrotide (DF) in the Treatment of Severe Hepatic Veno-Occlusive Disease (VOD) with Multi-Organ Failure (MOF) Following Stem Cell Transplantation (SCT): Results of a Phase 3 Study Utilizing a Historical Control.. Blood. 114(22). 654–654. 15 indexed citations

14.

Jilani, Iman, M. Gorre, Hagop M. Kantarjian, et al.. (2007). A potential role for HSP90 inhibitors in the treatment of JAK2 mutant-positive diseases as demonstrated using quantitative flow cytometry. Leukemia & lymphoma. 48(11). 2189–2195. 20 indexed citations

15.

Richardson, Paul G., Asher Chanan‐Khan, Sagar Lonial, et al.. (2007). Tanespimycin (T) + Bortezomib (BZ) in Multiple Myeloma (MM): Confirmation of the Recommended Dose Using a Novel Formulation.. Blood. 110(11). 1165–1165. 24 indexed citations

16.

Richardson, Paul G., Asher Chanan‐Khan, Sagar Lonial, et al.. (2007). Tanespimycin (T) + bortezomib (BZ) in multiple myeloma (MM): Pharmacology, safety and activity in relapsed/refractory (rel/ref) patients (Pts). Journal of Clinical Oncology. 25(18_suppl). 3532–3532. 8 indexed citations

17.

Modi, Shanu, Alison Stopeck, Michael S. Gordon, et al.. (2007). Combination of Trastuzumab and Tanespimycin (17-AAG, KOS-953) Is Safe and Active in Trastuzumab-Refractory HER-2–Overexpressing Breast Cancer: A Phase I Dose-Escalation Study. Journal of Clinical Oncology. 25(34). 5410–5417. 266 indexed citations

18.

Adamson, Peter C., Susan M. Blaney, Brenda J. Kitchen, et al.. (2004). Pediatric phase I trial and pharmacokinetic study of the platelet-derived growth factor (PDGF) receptor pathway inhibitor SU101. Cancer Chemotherapy and Pharmacology. 53(6). 482–488. 25 indexed citations

19.

London, Cheryl A., Alison L. Hannah, May Chien, et al.. (2003). Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies.. PubMed. 9(7). 2755–68. 220 indexed citations

20.

Eckhardt, S. Gail, Jinee Rizzo, Kevin Sweeney, et al.. (1999). Phase I and Pharmacologic Study of the Tyrosine Kinase Inhibitor SU101 in Patients With Advanced Solid Tumors. Journal of Clinical Oncology. 17(4). 1095–1095. 55 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact